v3.22.2.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net sales
Cost of sales
Gross profit
Operating expenses:        
Research and development, net of grants 3,855 2,868 9,738 8,027
Clinical and regulatory, net of grants 4 4
General and administrative 1,585 617 3,709 1,748
Total operating expenses 5,444 3,485 13,451 9,775
Loss from operations (5,444) (3,485) (13,451) (9,775)
Other income (expense), net 6,867 (6) 6,846 622
Net income/(loss) $ 1,423 $ (3,491) $ (6,605) $ (9,153)
Net income/(loss) per common share – basic $ 0.04 $ (0.10) $ (0.18) $ (0.28)
Net income/(loss) per common share – diluted $ 0.04 $ (0.10) $ (0.18) $ (0.28)
Weighted average common shares outstanding – basic 37,965 33,799 37,712 32,771
Weighted average common shares outstanding – diluted 38,477 33,799 37,712 32,771

Source